Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

White House Advances War On 'Guidance'; FDA Not Target, But May Feel Ripple Effects

Executive Summary

US FDA's efforts to enforce against regenerative medicine and other gray market products might be collateral damage in Trump administration's latest attack on the perceived abuse of powers by regulatory agencies.

You may also be interested in...



US FDA Guidance Production May Be Slowed By New OMB Review Requirement

White House says all guidances, as well as proposed rules, must be submitted to OMB for a determination whether they are major or minor.

'Just Say It!' – New Streamlined Guidance Format Coming, FDA's Woodcock Says

US guidances will be shorter and use a series of bullet points to communicate key ideas, replacing the current longer and wordier format.

Supreme Court’s Pro-Pharma Decision On Sales Rep Overtime Reproves Informal Agency Policymaking

Court rules that reps’ nonbinding commitments from physicians to prescribe drugs constitute a sale and thus make them outside sales employees who are exempt from overtime. Court also rebukes Labor Department’s policy change outside of rulemaking.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel